Literature DB >> 25103596

The value of liver and spleen ADC measurements in the diagnosis and follow up of hepatic fibrosis in chronic liver disease.

Ö Tokgöz, I Unal, G Gedikli Turgut, S Yildiz.   

Abstract

AIMS: To evaluate the value of spleen and liver apparent diffusion coefficients (ADC) in chronic liver disease patients, with and without hepatocellular carcinoma (HCC), and to investigate the use of diffusion-weighted imaging (DWI) in the diagnosis and follow-up of hepatic fibrosis.
MATERIALS AND METHODS: This study population comprised 68 chronic liver disease patients (Group 1) and 70 healthy volunteers as controls (Group 2). In Group 1, 40 patients had chronic hepatitis-B, 20 had chronic hepatitis-C, 5 had non-alcoholic steatohepatitis and 3 had alcoholic steatohepatitis. Diagnosis of chronic liver disease was made by percutaneous liver biopsy and the degree of fibrosis (stage) was determined using the METAVIR scoring system. HCC diagnosis was made with a lesion biopsy. The patient group was subdivided based on the degree of fibrosis (F1, F2, F3 and F4) and presence of HCC. After patient and control groups underwent b-value 600 s/mm(2) DWI examination, liver and spleen ADC values were mapped and measured. The ADC values of the patient groups (F1, F2, F3, F4; with HCC, without HCC) were compared with each other and with the control group.
RESULTS: Liver ADC values were lower in Group 1 compared to Group 2 (P<0·001). There was a statistically significant difference between the patient and control groups liver right lobe, left lobe and caudate lobe ADC values (P<0·001). Comparing the F1, F2, F3 and F4 groups, there was no statistically significant difference found in terms of ADC values (P>0·05). However, as degree of fibrosis increased there was a reduction in ADC values, though not statistically significant. Comparing the groups with HCC and without HCC, there was no statistically significant difference in ADC values (P>0·05). There was no statistical difference in average spleen ADC values between patient and control groups (P>0·05).
CONCLUSIONS: In chronic liver disease, ADC values were lower. As the degree of liver fibrosis increased, ADC levels decreased, though the relationship between ADC values and fibrosis degree was not statistically significant. Quantitative DWI may help in the diagnosis of fibrosis in chronic liver disease patients, however as it does not show the degree of fibrosis, its use in treatment planning and follow-up is controversial. Spleen DWI measurement is not a sufficient method to diagnose and determine the degree of fibrosis in chronic liver disease patients.

Entities:  

Keywords:  Apparent diffusion coefficients,; Disease,; Fibrosis,; Liver,; Spleen

Mesh:

Year:  2014        PMID: 25103596     DOI: 10.1179/2295333714Y.0000000062

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  7 in total

1.  Apparent diffusion coefficient measurements and Gd-DTPA enhanced-imaging in staging hepatic fibrosis in rats.

Authors:  Yi-Ping Zhao; Dong-Mei Guo; Hui Liu; Wen-Hong Liu; Wen-Ying Mu; Peng Zhang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Comparison of diffusion-weighted imaging and MR elastography in staging liver fibrosis: a meta-analysis.

Authors:  Weon Jang; Seongil Jo; Ji Soo Song; Hong Pil Hwang; Seong-Hun Kim
Journal:  Abdom Radiol (NY)       Date:  2021-03-26

Review 3.  Noninvasive imaging of hepatic dysfunction: A state-of-the-art review.

Authors:  Ting Duan; Han-Yu Jiang; Wen-Wu Ling; Bin Song
Journal:  World J Gastroenterol       Date:  2022-04-28       Impact factor: 5.374

4.  Comparison of the effect of region-of-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis.

Authors:  Ying Ding; Shengxiang Rao; Li Yang; Caizhong Chen; Mengsu Zeng
Journal:  Radiol Med       Date:  2016-07-23       Impact factor: 3.469

Review 5.  Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives.

Authors:  N M deSouza; J M Winfield; J C Waterton; A Weller; M-V Papoutsaki; S J Doran; D J Collins; L Fournier; D Sullivan; T Chenevert; A Jackson; M Boss; S Trattnig; Y Liu
Journal:  Eur Radiol       Date:  2017-09-27       Impact factor: 5.315

6.  Diagnostic value of magnetic resonance parametric mapping for non-invasive assessment of liver fibrosis in patients with primary sclerosing cholangitis.

Authors:  Narine Mesropyan; Patrick Kupczyk; Guido M Kukuk; Leona Dold; Tobias Weismueller; Christoph Endler; Alexander Isaak; Anton Faron; Alois M Sprinkart; Claus C Pieper; Daniel Kuetting; Christian P Strassburg; Ulrike I Attenberger; Julian A Luetkens
Journal:  BMC Med Imaging       Date:  2021-04-07       Impact factor: 1.930

7.  Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C: T1 mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging.

Authors:  Shen Pan; Xiao-Qi Wang; Qi-Yong Guo
Journal:  World J Gastroenterol       Date:  2018-05-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.